Joshua Rosenberg, MD

Early international experience and evolving real-world data indicate that the new MBL-targeting regimen shows strong potential for US clinicians, despite expected resistance patterns and still-developing evidence.

Clinicians should view the open-label data as promising but preliminary, with post-marketing evidence expected to play a critical role in defining its place in guidelines for treating MBL-producing, multidrug-resistant infections.

Aztreonam-avibactam achieved noninferior clinical cure rates and a comparable safety profile to meropenem/colistin, even amid a high proportion of carbapenemase-producing pathogens.

Joshua Rosenberg, MD, continues the discussion on the REVISIT study, which showed comparable—or lower—28-day mortality rates than meropenem/colistin despite treating a higher proportion of patients with metallo-β-lactamase–producing pathogens.

Joshua Rosenberg, MD, discuses the differences in clinical trials that enroll both intra-abdominal infection patients and those with hospital- or ventilator-associated pneumonia face major complexity because these two groups differ widely in baseline severity, mortality risk, and expected treatment outcomes

A novel pairing of aztreonam and avibactam offers a long-needed solution to combat highly drug-resistant gram-negative bacteria, particularly those producing difficult-to-treat metallo-β-lactamases.